We have participated in the first close of the USD 8M Series B funding round for Retinai, alongside Sanoptis, THINC Ventures (Topcon Healthcare), and?Zürcher Kantonalbank. This investment reinforces our commitment to advancing AI-driven solutions in ophthalmology, optometry, and beyond. By supporting RetinAI/Ikerian, we are helping accelerate the development of their powerful platforms— RetinAI Discovery? and Discovery CONNECT?— which are set to revolutionize data connectivity and enhance patient care across European clinics. RetinAI is also broadening its reach into new therapeutic areas, including neurodegenerative disorders and rare diseases, through its mother brand, Ikerian. It is leveraging real-world evidence (RWE) and AI to transform healthcare decision-making. Press release:?https://lnkd.in/ei8x7-w6
Verve Ventures的动态
最相关的动态
-
New partnership in eye care! Read our article here https://lnkd.in/gHPmNR2v to learn how Bausch + Lomb and Character Biosciences are teaming up to rewrite the playbook for age-related macular degeneration (AMD). This collaboration combines Bausch + Lomb's decades of expertise in ophthalmology with Character Bio's innovative data platform and AI-driven analytics to bring personalized therapies for AMD patients. #Ophthalmology #AMD #BauschandLomb #PIEMagazine #MediaMICE
-
-
Unlock the secrets to successful ophthalmology clinical operations with First in Human: The Panel Series. Hear from leading experts on collaboration, protocol development, and overcoming trial challenges. Watch here: https://lnkd.in/d2Xh-8TZ
-
-
?? Sign up for our July 11 webinar! Our experts Todd Rudo, Amit Vasanji, and Kelly Dumais will explore strategies to enhance patient access and precision analysis using artificial intelligence (#AI) in ophthalmology clinical trials. We’ll dive into: ??Vendor-agnostic, multi-modality platforms ??AI-enabled workflows ??Best practices for eCOA implementation in various trial settings ?? Register now and don’t miss the opportunity to learn how AI transforms ophthalmology clinical trials: https://lnkd.in/etkm-Xnt #artificialintelligence #clinicaltrials #ophthalmology
-
?? Sign up for our July 11 webinar! Our experts Todd Rudo, Amit Vasanji, and Kelly Dumais will explore strategies to enhance patient access and precision analysis using artificial intelligence (#AI) in ophthalmology clinical trials. We’ll dive into: ??Vendor-agnostic, multi-modality platforms ??AI-enabled workflows ??Best practices for eCOA implementation in various trial settings ?? Register now and don’t miss the opportunity to learn how AI transforms ophthalmology clinical trials: https://lnkd.in/eJYY7Rgf #artificialintelligence #clinicaltrials #ophthalmology
Revolutionizing Ophthalmology Clinical Trials Through Enhanced Accessibility and Advanced AI-driven Analysis | Clario
clario.shp.so
-
Accomplished event leader delivering strategic innovation for successful results
?? Sign up for our July 11 webinar! Our experts Todd Rudo, Amit Vasanji, and Kelly Dumais will explore strategies to enhance patient access and precision analysis using artificial intelligence (#AI) in ophthalmology clinical trials. We’ll dive into: ??Vendor-agnostic, multi-modality platforms ??AI-enabled workflows ??Best practices for eCOA implementation in various trial settings ?? Register now and don’t miss the opportunity to learn how AI transforms ophthalmology clinical trials: https://lnkd.in/eRBrcDtQ #artificialintelligence #clinicaltrials #ophthalmology
Revolutionizing Ophthalmology Clinical Trials Through Enhanced Accessibility and Advanced AI-driven Analysis | Clario
clario.shp.so
-
?? Sign up for our July 11 webinar! Our experts Todd Rudo, Amit Vasanji, and Kelly Dumais will explore strategies to enhance patient access and precision analysis using artificial intelligence (#AI) in ophthalmology clinical trials. We’ll dive into: ??Vendor-agnostic, multi-modality platforms ??AI-enabled workflows ??Best practices for eCOA implementation in various trial settings ?? Register now and don’t miss the opportunity to learn how AI transforms ophthalmology clinical trials: https://lnkd.in/dv-5-y3R #artificialintelligence #clinicaltrials #ophthalmology
Revolutionizing Ophthalmology Clinical Trials Through Enhanced Accessibility and Advanced AI-driven Analysis | Clario
clario.shp.so
-
At last month’s OIS XIV in San Diego, Onsite Insights host Bindu Manne sat down with Daniela Ferrara, MD PhD FASRS, a pioneer in AI, to discuss how artificial intelligence is transforming drug development and clinical trials. Dr. Ferrara shared insights on Genentech and Roche’s groundbreaking ophthalmology imaging program, highlighting how AI-driven analytics are enhancing trial design, patient selection, and clinical assessments. ?? ?????????? ???????? ???????????????????? ???????????????????????? ???? ????’?? ???????? ???? ?????????????????????????? ?????? ?????? ?????????? ???? ?????????? ?????? ???????????? ???? ?????????????? ????????. ?????????? ??????! https://lnkd.in/e9K8KtzN #OISXIV #OnsiteInsights #AIinHealthcare #Ophthalmology #ClinicalTrials #Innovation
-
Medical & Scientific Writer | Clinical & Regulatory Affairs Specialist | Medical Devices | Researcher ??? | Beginner Runner ????♀? | Mosaic Lover ????
Proud to be part of this team! At Retinai, the Research Team is dedicated to elevating your research & data analysis with the efficiency our AI technology enables. Whether you are focused on clinical trials, drug development or academia, we are here to offer technology solutions that are tailored to your needs.? Check out our most recent Blog Post to see how can we help you elevate your #research and #dataanalysis! Joseph Blair, Adrian Kaufmann, Sandro De Zanet #research #ophthalmology #AI
How can Retinai Discovery? take your research and data analysis to the next level? Our platform streamlines your clinical trials and academic research with a smooth 3-step process: 1?? Planning 2?? Analysis 3?? Reporting Find out how we customize our AI-driven solutions to fit your unique needs and advance your work in ophthalmology. Explore the benefits of collaborating with Retinai and how we can enhance your research outcomes in our latest blog ?? https://lnkd.in/enjxzVjF #Innovation #HealthTech #EyeHealth Romina Lasagni Vitar, PhD Joseph Blair
-
-
Important end point for clinical trials...Ellipsoid Zone loss....using these analyses, we will be able to identify early progressors and treatment response.
Excited to share that Netramind Innovations has developed an advanced AI solution for drusen area measurements, geographic atrophy measurements, and ellipsoid zone measurements—recently recognized as a clinical trial endpoint by the #FDA. This breakthrough technology streamlines retinal disease analysis and supports more accurate and efficient clinical trials. Proud to see how AI is revolutionizing ophthalmology and advancing patient care! #AI #Ophthalmology #ClinicalTrials #Innovation #NetramindInnovations #Retina #FDA #HealthcareTechnology #AMD #Retina Jay Chhablani Kiran Vupparaboina Sandeep Chandra Choroidal Analysis Research Lab
-
Cool stuff for eCOA and Imaging in ophthalmology research! ?? Sign up for our July 11 webinar! Our experts Todd Rudo, Amit Vasanji, and Kelly Dumais will explore strategies to enhance patient access and precision analysis using artificial intelligence (#AI) in ophthalmology clinical trials. We’ll dive into: ??Vendor-agnostic, multi-modality platforms ??AI-enabled workflows ??Best practices for eCOA implementation in various trial settings ?? Register now and don’t miss the opportunity to learn how AI transforms ophthalmology clinical trials: https://lnkd.in/eYh52nv7 #artificialintelligence #clinicaltrials #ophthalmology
Revolutionizing Ophthalmology Clinical Trials Through Enhanced Accessibility and Advanced AI-driven Analysis | Clario
clario.shp.so
--
4 个月Glückwunsch!